Donor-specific antibodies in liver transplantation.
Vionnet JInstitute of Liver Studies, King's College Hospital, London, United Kingdom; Transplantation Centre, University Hospital of Lausanne, Lausanne, Switzerland; Service of Gastroenterology and Hepatology, University Hospital of Lausanne, Lausanne, Switzerland. Electronic address: Julien.Vionnet@kcl.ac.uk.
Sempoux CInstitute of Pathology, University Hospital of Lausanne, Lausanne, Switzerland.
Pascual MTransplantation Centre, University Hospital of Lausanne, Lausanne, Switzerland.
Sánchez-Fueyo AInstitute of Liver Studies, King's College Hospital, London, United Kingdom.
Colmenero JHospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
English
Despite unique immunoregulatory properties pointing toward tolerance, the liver allograft can be negatively impacted by humoral alloreactivity, with immediate as well as long-term harmful consequences. With regard to the unmet need of long-term outcomes improvement after liver transplantation, donor-specific antibodies have recently been the matter of intense study in this context. We review here recent advances regarding the understanding of the impact of preformed as well as de novo anti-human leukocyte antigen donor-specific antibodies in liver transplantation and discuss potential strategies to overcome this problem.